Login Register Cart 0
Generic placeholder image

Pharmaceutical Nanotechnology

Editor-in-Chief

ISSN (Print): 2211-7385
ISSN (Online): 2211-7393

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In-situ Intestinal Absorption and Pharmacokinetic Investigations of Carvedilol Loaded Supersaturated Self-emulsifying Drug System

Author(s): Vamshi M. Krishna, Vijaya B. Kumar and Narendar Dudhipala*

Volume 8, Issue 3, 2020

Page: [207 - 224] Pages: 18

DOI: 10.2174/2211738508666200517121637

Price: $65

Abstract

Background: Carvedilol (CD), a non-selective beta-blocker, is indicated for the management of mild to moderate congestive heart failure. After oral administration, CD is rapidly absorbed with an absolute bioavailability of 18-25% because of low solubility and extensive first-pass metabolism.

Objective: The present investigation focused on enhanced oral delivery of CD using supersaturated self-emulsifying drug delivery (SEDDS) system.

Methods: Optimized SEDDS consisted of a blend of Oleic acid and Labrafil-M2125 as an oil-phase, Cremophor-RH40, polyethylene glycol-400 and HPMC-E5 as a surfactant, co-surfactant and supersaturation promoter respectively. Formulations were characterized for physical characteristics, invitro release in simulated and biorelevant dissolution media, intestinal permeability and bioavailability studies in Wistar rats. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) analysis, scanning electron microscopy (SEM) studies were used to confirm the crystalline nature and shape of the optimized formulation.

Results: DSC and XRD, SEM studies showed that the drug was in amorphous form, and droplets were spherical in shape. Dissolution studies clearly showed distinct CD release in compendial and biorelevant dissolution media. The results from permeability and in-vivo studies depicted 2.2-folds and 3.2-folds increase in permeability and bioavailability, respectively from supersaturated SEDDS in comparison with control.

Conclusion: The results conclusively confirmed that the SEDDS formulation could be considered as a new alternative delivery vehicle for the oral supply of CD.

Lay Summary: Carvedilol (CD) is a non-selective antihypertensive drug with poor oral bioavailability. Previously, various lipid delivery systems were reported with enhanced oral delivery. We developed suprsaturable SEDDS formulation with immediate onset of action. SEDDS formulation was developed and optimized as per the established protocols. The optimized SEDDS formulation was stable over three months and converted to solid and supersaturated SEDDS. The results from permeability and in-vivo studies demonstrated an enhancement in permeability and bioavailability from supersaturated SEDDS in comparison with control. The results conclusively confirmed that the SEDDS formulation could be considered as a new alternative delivery vehicle for the oral administration of CD.

Keywords: Bioavailability, biorelevant media, carvedilol, intestinal permeability, SEDDS, super saturation promoter.

« Previous Next »
Graphical Abstract

[1]
Aungst BJ. Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 1993; 82(10): 979-87.
[http://dx.doi.org/10.1002/jps.2600821008] [PMID: 8254497]
[2]
Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Drug Dev Ind Pharm 2017; 43(7): 1186-96.
[http://dx.doi.org/10.1080/03639045.2017.1304955] [PMID: 28271908]
[3]
Palem CR, Gannu R, Doodipala N, Yamsani VV, Yamsani MR. Transmucosal delivery of domperidone from bilayered buccal patches: in vitro, ex vivo and in vivo characterization. Arch Pharm Res 2011; 34(10): 1701-10.
[http://dx.doi.org/10.1007/s12272-011-1014-2] [PMID: 22076770]
[4]
Reddy PC, Narendar D, Sunil KB, Goda S, Rao MY. Combined dosage form of pioglitazone and felodipine as mucoadhesive pellets via hot melt extrusion for improved buccal delivery with application of quality by design approach. J Drug Deliv Sci Technol 2015; 30: 209-19.
[http://dx.doi.org/10.1016/j.jddst.2015.10.017]
[5]
Shruthi K, Narendar D, Arjun N, Kishan V. Development and antimicrobial evaluation of binary ethosomal topical gel of terbinafine hydrochloride for the treatment of onychomycosis. Int J Pharm Sci Nanotechnol 2018; 11(1): 3998-4005.
[6]
Pitta S, Dudhipala N, Narala A, Veerabrahma K. Development and evaluation of zolmitriptan transfersomes by Box-Behnken design for improved bioavailability by nasal delivery. Drug Dev Ind Pharm 2018; 44(3): 484-92.
[http://dx.doi.org/10.1080/03639045.2017.1402918] [PMID: 29124986]
[7]
Janga KY, Tatke A, Dudhipala N, et al. Gellan gum based sol-to-gel transforming system of natamycin transfersomes improves topical ocular delivery. J Pharmacol Exp Ther 2019; 370(3): 814-22.
[http://dx.doi.org/10.1124/jpet.119.256446] [PMID: 30872389]
[8]
Swetha E, Narendar D. Influence of β-cyclodextrin and hydroxypropyl-β-cyclodextrin on enhancement of solubility and dissolution of isradipine. Int J Pharm Sci Nanotechnol 2017; 10(3): 3752-7.
[9]
Arun B, Narendar D. Enhancement of solubility and dissolution rate of trandolapril sustained release matrix tablets by liquisolid compact approach. Asian J Pharm 2015; 9(4): 290-7.
[10]
Narendar D, Someshwar K, Arjun N, Yamsani MR. Quality by design approach for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets for improved oral delivery. J Pharm Investig 2016; 46(3): 253-63.
[http://dx.doi.org/10.1007/s40005-016-0232-5]
[11]
Narendar D, Palem CR, Reddy S, Rao YM. Pharmaceutical development and clinical pharmacokinetic evaluation of gastroretentive floating matrix tablets of levofloxacin. Int J Pharm Sci Nanotechnol 2011; 4(3): 1461-7.
[12]
Narendar D, Arjun N, Karthik YJ. Ramesh Bomma.. Amoxycillin trihydrate floating-bioadhesive drug delivery system for eradication of helicobacter pylori: preparation, in vitro and ex vivo evaluation. J bioequ avail 2016; 8(3): 118-24.
[13]
Gupta A, Aggarwal G, Singla S, Arora R. Transfersomes: a novel vesicular carrier for enhanced transdermal delivery of sertraline: development, characterization, and performance evaluation. Scient pharmace 2012; 80(4): 1061-80.
[http://dx.doi.org/10.3797/scipharm.1208-02]
[14]
Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine 2006; 1(3): 297.
[15]
Dudhipala N, Puchchakayala G. Capecitabine lipid nanoparticles for anti-colon cancer activity in 1,2-dimethylhydrazine-induced colon cancer: preparation, cytotoxic, pharmacokinetic, and pathological evaluation. Drug Dev Ind Pharm 2018; 44(10): 1572-82.
[http://dx.doi.org/10.1080/03639045.2018.1445264] [PMID: 29493289]
[16]
Humberstone AJ, Charman WN. Lipid based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 1997; 25: 103-28.
[http://dx.doi.org/10.1016/S0169-409X(96)00494-2]
[17]
Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci 2006; 29(3-4): 278-87.
[http://dx.doi.org/10.1016/j.ejps.2006.04.016] [PMID: 16815001]
[18]
Kommuru TR, Gurley B, Khan MA, Reddy IK. Self-emulsifying drug delivery systems (SEDDS) of coenzyme Q10: formulation development and bioavailability assessment. Int J Pharm 2001; 212(2): 233-46.
[http://dx.doi.org/10.1016/S0378-5173(00)00614-1] [PMID: 11165081]
[19]
Nazzal S, Khan MA. Controlled release of a self-emulsifying formulation from a tablet dosage form: stability assessment and optimization of some processing parameters. Int J Pharm 2006; 315(1-2): 110-21.
[http://dx.doi.org/10.1016/j.ijpharm.2006.02.019] [PMID: 16563673]
[20]
Shah NH, Carvajal MT, Patel CI, Infeld MH, Malick AW. Self-emulsifying drug delivery systems (SEDDS) with polyglycolysed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. Int J Pharm 1994; 106: 15-23.
[http://dx.doi.org/10.1016/0378-5173(94)90271-2]
[21]
Gursoy RN, Benita S. Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 2004; 58(3): 173-82.
[http://dx.doi.org/10.1016/j.biopha.2004.02.001] [PMID: 15082340]
[22]
Narendar D. A comprehensive review on solid lipid nanoparticles as delivery vehicle for enhanced pharmacokinetic and pharmacodynamic activity of poorly soluble drugs. Int J Pharm Sci Nanotech 2019; 12(2): 4421-40.
[23]
Jannin V, Musakhanian J, Marchaud D. Approaches for the development of solid and semi-solid lipid-based formulations. Adv Drug Deliv Rev 2008; 60(6): 734-46.
[http://dx.doi.org/10.1016/j.addr.2007.09.006] [PMID: 18045728]
[24]
Hauss DJ, Fogal SE, Ficorilli JV, et al. Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. J Pharm Sci 1998; 87(2): 164-9.
[http://dx.doi.org/10.1021/js970300n] [PMID: 9519148]
[25]
Anayatollah S, Behzad S, Makhmal Z, et al. Design and evaluation of self-emulsifying drug delivery system (SEDDS) of carvedilol to improve the oral absorption. Jundishapur J Nat Pharm Prod 2014; 9(3): e16125
[26]
Silva LAD, Almeida SL, Alonso ECP, et al. Preparation of a solid self-microemulsifying drug delivery system by hot-melt extrusion. Int J Pharm 2018; 541(1-2): 1-10.
[http://dx.doi.org/10.1016/j.ijpharm.2018.02.020] [PMID: 29458210]
[27]
Ibrahim TM, Abdallah MH, El-Megrab NA, El-Nahas HM. Upgrading of dissolution and anti-hypertensive effect of Carvedilol via two combined approaches: self-emulsification and liquisolid techniques. Drug Dev Ind Pharm 2018; 44(6): 873-85.
[http://dx.doi.org/10.1080/03639045.2017.1417421] [PMID: 29254384]
[28]
Balakrishnan P, Lee BJ, Oh DH, et al. Enhanced oral bioavailability of dexibuprofen by a novel solid self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm 2009; 72(3): 539-45.
[http://dx.doi.org/10.1016/j.ejpb.2009.03.001] [PMID: 19298857]
[29]
Wei L, Sun P, Nie S, Pan W. Preparation and evaluation of SEDDS and SMEDDS containing carvedilol. Drug Dev Ind Pharm 2005; 31(8): 785-94.
[http://dx.doi.org/10.1080/03639040500216428] [PMID: 16221613]
[30]
Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. Drug Dev Ind Pharm 2015; 41(12): 1968-77.
[http://dx.doi.org/10.3109/03639045.2015.1024685] [PMID: 25830370]
[31]
Gargouri Y, Pieroni G, Rivière C, et al. Importance of human gastric lipase for intestinal lipolysis: an in vitro study. Biochim Biophys Acta 1986; 879(3): 419-23.
[http://dx.doi.org/10.1016/0005-2760(86)90234-1] [PMID: 3778930]
[32]
Fernandez S, Jannin V, Rodier JD, Ritter N, Mahler B, Carrière F. Comparative study on digestive lipase activities on the self-emulsifying excipient Labrasol, medium chain glycerides and PEG esters. Biochim Biophys Acta 2007; 1771(5): 633-40.
[http://dx.doi.org/10.1016/j.bbalip.2007.02.009] [PMID: 17418634]
[33]
Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6(3): 231-48.
[http://dx.doi.org/10.1038/nrd2197] [PMID: 17330072]
[34]
Pouton CW. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and ‘self-microemulsifying’ drug delivery systems. Eur J Pharm Sci 2000; 11(Suppl. 2): S93-8.
[http://dx.doi.org/10.1016/S0928-0987(00)00167-6] [PMID: 11033431]
[35]
Macgregor KJ, Embleton JK, Lacy JE. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliv Rev 1997; 25: 33-46.
[http://dx.doi.org/10.1016/S0169-409X(96)00489-9]
[36]
Sek L, Porter CJ, Charman WN. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis. J Pharm Biomed Anal 2001; 25(3-4): 651-61.
[http://dx.doi.org/10.1016/S0731-7085(00)00528-8] [PMID: 11377046]
[37]
Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. AAPS J 2010; 12(3): 397-406.
[http://dx.doi.org/10.1208/s12248-010-9203-3] [PMID: 20458565]
[38]
Hitesh J, Surya PS, Lovleen KG. A simple, safe, and environmentally friendly method of fassif and fessif preparation without methylene chloride. Diss Techn 2014; 2: 45-8.
[39]
Sakina F, Shahnaz G, Rabia IY. Biorelevant dissolution media: a predictive means for in vivo performance of simvastatin tablets. Int J Biopharm 2013; 4(3): 214-8.
[40]
Balakumar K, Raghavan CV. selvan NT, prasad RH, Abdu S. Self nanoemulsifying drug delivery system (SNEDDS) of rosuvastatin calcium: design, formulation, bioavailability and pharmacokinetic evaluation. Colloids Surf B Biointerfaces 2013; 112: 337-43.
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.025] [PMID: 24012665]
[41]
Dudhipala N, Janga KY, Gorre T. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol 2018; 46(sup2): 616-25.
[http://dx.doi.org/10.1080/21691401.2018.1465068] [PMID: 29688077]
[42]
Dudhipala N, Veerabrahma K. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 2016; 23(2): 395-404.
[http://dx.doi.org/10.3109/10717544.2014.914986] [PMID: 24865287]
[43]
Janga KY, Jukanti R, Velpula A, et al. Bioavailability enhancement of zaleplon via proliposomes: role of surface charge. Eur J Pharm Biopharm 2012; 80(2): 347-57.
[http://dx.doi.org/10.1016/j.ejpb.2011.10.010] [PMID: 22041602]
[44]
Cutler DJ. Theory of the mean absorption time, an adjunct to conventional bioavailability studies. J Pharm Pharmacol 1978; 30(8): 476-8.
[http://dx.doi.org/10.1111/j.2042-7158.1978.tb13296.x] [PMID: 28392]
[45]
Cuiné JF, Charman WN, Pouton CW, Edwards GA, Porter CJ. Increasing the proportional content of surfactant (Cremophor EL) relative to lipid in self-emulsifying lipid-based formulations of danazol reduces oral bioavailability in beagle dogs. Pharm Res 2007; 24(4): 748-57.
[http://dx.doi.org/10.1007/s11095-006-9194-z] [PMID: 17372700]
[46]
Qingxi W, Nikoletta F, Yun M. Biorelevant dissolution: methodology and application in drug development. Diss Techn 2009; 16(3): 6-12.
[47]
Dahan A, Hoffman A. Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. Pharm Res 2006; 23(9): 2165-74.
[http://dx.doi.org/10.1007/s11095-006-9054-x] [PMID: 16902814]
[48]
Porter CJ, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res 2004; 21(8): 1405-12.
[http://dx.doi.org/10.1023/B:PHAM.0000036914.22132.cc] [PMID: 15359575]
[49]
Cuiné JF, McEvoy CL, Charman WN, et al. Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs. J Pharm Sci 2008; 97(2): 995-1012.
[http://dx.doi.org/10.1002/jps.21246] [PMID: 18064698]
[50]
Kang BK, Lee JS, Chon SK, et al. Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. Int J Pharm 2004; 274(1-2): 65-73.
[http://dx.doi.org/10.1016/j.ijpharm.2003.12.028] [PMID: 15072783]
[51]
Sun D, Wei X, Xue X, et al. Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-α-tocopheryl polyethylene glycol 1000 succinate nanoemulsions. Int J Nanomedicine 2014; 9: 3413-23.
[PMID: 25071371]
[52]
Dudhipala N, Veerabrahma K. Improved anti-hyperlipidemic activity of rosuvastatin calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Eur J Pharm Biopharm 2017; 110: 47-57.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.022] [PMID: 27810472]
[53]
Veerabrahma K. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. Artif Cells Nanomed Biotechnol 2018; 46(1): 126-37.
[http://dx.doi.org/10.1080/21691401.2017.1299160] [PMID: 28290712]

Rights & Permissions Print Cite
Article Metrics
14
© 2024 Bentham Science Publishers | Privacy Policy